The Nationwide Fund Advisors sells partial stakes of Neurocrine Biosciences Inc. (NBIX)

The Nationwide Fund Advisors sells partial stakes of Neurocrine Biosciences Inc. (NBIX)

Nationwide Fund Advisors lowered its stake in Neurocrine Biosciences Inc. (NASDAQ:NBIX) by 50.6% during the second quarter, Holdings Channel reports. The institutional investor owned 46,058 shares of the company’s stock after selling 47,098 shares during the period. Nationwide Fund Advisors owned approximately 0.05% of Neurocrine Biosciences worth $2,093,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Natixis boosted its stake in Neurocrine Biosciences by 0.7% in the first quarter. Natixis now owns 8,891 shares of the company’s stock valued at $352,000 after buying an additional 66 shares in the last quarter. Mutual of America Capital Management LLC boosted its stake in Neurocrine Biosciences by 0.3% in the second quarter. Mutual of America Capital Management LLC now owns 71,904 shares of the company’s stock valued at $3,268,000 after buying an additional 200 shares in the last quarter. Springbok Capital Management LLC boosted its stake in Neurocrine Biosciences by 5.5% in the first quarter. Springbok Capital Management LLC now owns 7,061 shares of the company’s stock valued at $279,000 after buying an additional 367 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Neurocrine Biosciences by 4.8% in the second quarter. BNP Paribas Arbitrage SA now owns 12,736 shares of the company’s stock valued at $579,000 after buying an additional 583 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Neurocrine Biosciences by 12.3% in the second quarter. Janney Montgomery Scott LLC now owns 10,020 shares of the company’s stock valued at $567,000 after buying an additional 1,096 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) traded up 1.95% during mid-day trading on Thursday, hitting $43.91. 370,610 shares of the stock were exchanged. Neurocrine Biosciences Inc. has a 12-month low of $31.25 and a 12-month high of $58.46. The firm has a 50-day moving average price of $50.47 and a 200 day moving average price of $47.60. The company’s market capitalization is $3.81 billion.

Several research firms recently commented on NBIX. TheStreet cut shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, July 14th. Leerink Swann restated an “outperform” rating and set a $70.00 price target on shares of Neurocrine Biosciences in a report on Wednesday. HC Wainwright assumed coverage on shares of Neurocrine Biosciences in a research note on Wednesday, June 29th. They issued a “buy” rating and a $80.00 target price for the company. Cowen and Company reiterated a “buy” rating and issued a $65.00 target price on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $66.00 target price on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $65.50.

In other Neurocrine Biosciences news, insider Christopher Flint Obrien sold 12,500 shares of the firm’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $48.73, for a total transaction of $609,125.00. Following the completion of the sale, the insider now owns 55,044 shares of the company’s stock, valued at approximately $2,682,294.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Corinne H. Nevinny sold 5,000 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $48.54, for a total value of $242,700.00. Following the sale, the director now directly owns 25,555 shares of the company’s stock, valued at approximately $1,240,439.70. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Related posts

Leave a Comment